Schizophrenia
is one of the most convoluted diseases of the human minds. Generally it appears
in late adolescent or early adulthood, but it is not limited by the age, it can
affect a person any time in his life. People with schizophrenia may hear voices
that are not present. The individual then tends to become an introvert,
sometimes even dangerous for him/herself and others. This disease affects males
and females equally. However, an article in BMJ
claims that it affects 1.4 males for every 1 female. According to WHO,
Schizophrenia affects about 24 million people worldwide.
Scientists think that nicotine in
tobacco may contribute in reducing the symptoms of schizophrenia temporarily.
People with this condition are not consciously aware of this addiction, that by
smoking they are actually self-medicating. The bad luck however is, that it
increases other risk factors like cancer, lung cancer, heart disease, stroke
and early death.
According to a new research, 75 % of the
people suffering from schizophrenia smoke. This is a rate thrice as much as the
smokers in the general population. Moreover, Schizophrenics inhale more deeply
and smoke more frequently than the smokers in general.
Bentham
Science Publishers is a rapidly growing scholarly journal
publisher and has been serving the academia and libraries for the last 25
years. They publish 122 subscription based journals, while their flagship
products include 32 journals with impact factors. One of Bentham Science
Publishers high impact factor
journals is ‘CNS
& Neurological Disorders - Drug Targets’
The journal publishes guest edited
thematic issues written by leaders in the field covering a range of current
topics of CNS & neurological drug targets. This journal is essential
reading for all pharmaceutical scientists involved in drug discovery and
development.
0 comments:
Post a Comment